NO20075618L - Novel compounds as GLP-1 Agonists - Google Patents
Novel compounds as GLP-1 AgonistsInfo
- Publication number
- NO20075618L NO20075618L NO20075618A NO20075618A NO20075618L NO 20075618 L NO20075618 L NO 20075618L NO 20075618 A NO20075618 A NO 20075618A NO 20075618 A NO20075618 A NO 20075618A NO 20075618 L NO20075618 L NO 20075618L
- Authority
- NO
- Norway
- Prior art keywords
- glp
- agonists
- novel compounds
- compounds
- diabetes
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 title 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000000816 peptidomimetic Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Det beskrives en gruppe nye peptidomimetika som er nyttige for behandling av diabetes. Disse forbindelser er definert ved den generelle formel (I). A-X1-S1-Y-S2-X2-B (I)A group of novel peptidomimetics useful for the treatment of diabetes is described. These compounds are defined by the general formula (I). A-X1-S1-Y-S2-X2-B (I)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN558MU2005 | 2005-05-05 | ||
| IN645MU2005 | 2005-05-31 | ||
| PCT/IN2006/000154 WO2007017892A2 (en) | 2005-05-05 | 2006-05-04 | Novel compounds as glp-i agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20075618L true NO20075618L (en) | 2008-01-30 |
Family
ID=37727716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20075618A NO20075618L (en) | 2005-05-05 | 2007-11-06 | Novel compounds as GLP-1 Agonists |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1891106A2 (en) |
| JP (1) | JP2008540402A (en) |
| KR (1) | KR20080021636A (en) |
| AP (1) | AP2007004227A0 (en) |
| AU (1) | AU2006277557A1 (en) |
| BR (1) | BRPI0612471A2 (en) |
| CA (1) | CA2606894A1 (en) |
| EA (1) | EA200702419A1 (en) |
| IL (1) | IL187105A0 (en) |
| MX (1) | MX2007013655A (en) |
| NO (1) | NO20075618L (en) |
| WO (1) | WO2007017892A2 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7534763B2 (en) | 2004-07-02 | 2009-05-19 | Bristol-Myers Squibb Company | Sustained release GLP-1 receptor modulators |
| EP2021014A1 (en) | 2006-05-26 | 2009-02-11 | Brystol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
| US8841413B2 (en) * | 2006-10-03 | 2014-09-23 | Cadila Healthcare Limited | Antidiabetic compounds |
| MX2010006287A (en) | 2007-12-11 | 2010-10-26 | Cadila Healthcare Ltd | Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities. |
| JP2011506376A (en) * | 2007-12-11 | 2011-03-03 | エフ．ホフマン−ラ ロシュ アーゲー | Insulin secretory peptide synthesis using combined solid and solution phase techniques |
| EP2424888A2 (en) * | 2009-05-01 | 2012-03-07 | F. Hoffmann-La Roche AG | Insulinotropic peptide synthesis using solid and solution phase combination techniques |
| CN101891823B (en) | 2010-06-11 | 2012-10-03 | 北京东方百泰生物科技有限公司 | Exendin-4 and analog fusion protein thereof |
| EP2956160B1 (en) * | 2013-02-15 | 2018-04-25 | Mayo Foundation For Medical Education And Research | Insulin secreting polypeptides |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
| GB0024428D0 (en) * | 2000-10-05 | 2000-11-22 | King S College | Absorption enhancers |
| EP1411968B1 (en) * | 2001-07-31 | 2008-09-17 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Glp-1 exendin-4 peptide analogs and uses thereof |
| US7238671B2 (en) * | 2001-10-18 | 2007-07-03 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| BR0306706A (en) * | 2002-01-08 | 2007-03-27 | Lilly Co Eli | glp-1 peptide extended, methods of glp-1 receptor stimulation in an individual requiring blood glucose normalization, treatment of an individual prophylactically for insulin-independent diabetes, reduction or maintenance of body weight, treatment of obesity , and treatment of diseases, in an individual in need thereof, use of a glp-1 compound, process of preparing a pharmaceutical formulation, and, pharmaceutical formulation. |
| RU2378285C2 (en) * | 2004-02-11 | 2010-01-10 | Амилин Фармасьютикалз, Инк. | Hybrid polypeptides with selectable properties |
| TW200611704A (en) * | 2004-07-02 | 2006-04-16 | Bristol Myers Squibb Co | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions |
| DE102004043153B4 (en) * | 2004-09-03 | 2013-11-21 | Philipps-Universität Marburg | Invention relating to GLP-1 and exendin |
-
2006
- 2006-05-04 AP AP2007004227A patent/AP2007004227A0/en unknown
- 2006-05-04 CA CA002606894A patent/CA2606894A1/en not_active Abandoned
- 2006-05-04 JP JP2008509578A patent/JP2008540402A/en not_active Withdrawn
- 2006-05-04 AU AU2006277557A patent/AU2006277557A1/en not_active Abandoned
- 2006-05-04 KR KR1020077028300A patent/KR20080021636A/en not_active Withdrawn
- 2006-05-04 WO PCT/IN2006/000154 patent/WO2007017892A2/en not_active Ceased
- 2006-05-04 BR BRPI0612471A patent/BRPI0612471A2/en not_active IP Right Cessation
- 2006-05-04 EP EP06809915A patent/EP1891106A2/en not_active Withdrawn
- 2006-05-04 EA EA200702419A patent/EA200702419A1/en unknown
- 2006-05-04 MX MX2007013655A patent/MX2007013655A/en not_active Application Discontinuation
-
2007
- 2007-11-01 IL IL187105A patent/IL187105A0/en unknown
- 2007-11-06 NO NO20075618A patent/NO20075618L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006277557A1 (en) | 2007-02-15 |
| CA2606894A1 (en) | 2007-02-15 |
| MX2007013655A (en) | 2008-01-24 |
| EP1891106A2 (en) | 2008-02-27 |
| WO2007017892A2 (en) | 2007-02-15 |
| EA200702419A1 (en) | 2008-04-28 |
| AP2007004227A0 (en) | 2007-12-31 |
| WO2007017892A3 (en) | 2007-09-20 |
| IL187105A0 (en) | 2008-02-09 |
| JP2008540402A (en) | 2008-11-20 |
| BRPI0612471A2 (en) | 2016-09-06 |
| KR20080021636A (en) | 2008-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20075618L (en) | Novel compounds as GLP-1 Agonists | |
| UY30371A1 (en) | CHEMICAL COMPOUNDS | |
| NO20075809L (en) | DNA-PK inhibitors | |
| EA201101004A1 (en) | FUNCTIONAL COMPOSITION | |
| NO20071901L (en) | Substituted bicyclic imidazo-3-ylamine compositions | |
| EA200970605A1 (en) | MAPK / ERK KINAZ INHIBITORS | |
| UY29612A1 (en) | CHEMICAL COMPOUNDS II | |
| NO20065613L (en) | 3-carbamoyl-2-pyridonderivat. | |
| TW200510381A (en) | Novel 2-pyridinecarboxamide derivatives | |
| CY1109911T1 (en) | PYRROLOVENZODIAZEPINES | |
| NO20082116L (en) | Chemical process for preparing an amido-phenoxybenzoic acid compound | |
| NO20080942L (en) | Amino-5- [4- (difluoromethoxy) phenyl] -5-phenylimidazolone compounds as inhibitors of beta-secretase (BACE) | |
| NO20084583L (en) | Macrocyclic kinase inhibitors | |
| MY153045A (en) | Oxopyrazine derivative and herbicide | |
| NO20074770L (en) | polyoxyalkylene | |
| NI200900151A (en) | NEW PROCEDURE FOR THE SYNTHESIS OF AGOMELATIN. | |
| NZ593172A (en) | 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2 | |
| NO20091858L (en) | Hydrobenzamide derivatives as inhibitors of HSP90 | |
| NO20082209L (en) | Homo and heterocyclic compounds useful as CETP inhibitors | |
| GEP20125512B (en) | Process for synthesis of agomelatin | |
| NO20082877L (en) | Precursor compound for radioactive halogen-labeled organic compound | |
| NO20074739L (en) | Amide derivatives such as ion channel ligands and pharmaceutical compositions and methods for using the same | |
| NO20091746L (en) | New diphenyllazetidinone substituted with piperazine-1-sulfonic acid with improved pharmacological properties | |
| EA201070138A1 (en) | PLEURROMUTILIN DERIVATIVES AND THEIR APPLICATION AS ANTIMICROBIAL MEANS | |
| NO20071012L (en) | Process for Preparation of D-Erythro-2,2-Difluoro-2-Deoxy-1-Oxoribose Derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |